• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jane C. Weeks, M.D. M.Sc. Sc.M.

Professor, Department of Medicine, Harvard Medical School

Professor, Department of Health Policy and Management, Harvard School Of Public Health

Chief, Population Science, Dana-Farber Cancer Institute

Contact Info

Jane Weeks
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: Building 454, Suite 21
Phone: 617-632-2509
Fax: 617-632-2270
jane_weeks@dfci.harvard.edu

Assistant

Susan Aoki
Administrative Specialist
Population Sciences
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: SM271
Phone: 617-632-4351
Fax: 617-632-2270
susan_aoki@dfci.harvard.edu

DF/HCC Program Affiliation

Breast Cancer
Outcomes Research, Co-Leader
Palliative Care
Lung Cancer
Lymphoma and Myeloma

DF/HCC Associations

Member, Center Scientific Council

Research Abstract

Dr. Weeks' research focuses on assessing the outcomes and cost effectiveness of cancer therapy. She is the Principal Investigator of one of the NCI-funded CanCORS studies examining the quality and outcomes of care for patients with lung and colorectal cancer across the US. She is also the Principal Investigator of the National Comprehensive Cancer Network (NCCN) Outcomes Project. In this role, she directs the collection and analysis of data on the clinical characteristics, treatment, and outcomes of cancer patients cared for in NCCN centers. She chairs the Clinical Economics Subcommittee of the CALGB, and is the lead investigator on a number of economic analyses alongside clinical trials in that group. Her primary methodologic interest is in assessing patients’ preferences for use in treatment and policy decision-making.

Publications

  • Lamont EB, Herndon JE, Weeks JC, Henderson IC, Earle CC, Schilsky RL, Christakis NA,.Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).J Natl Cancer Inst 2006 Sep 20;98
    16985253
  • Punglia RS, Weeks JC, Neville BA, Earle CC.Radiation therapy after mastectomy between 1991 and 1999 in elderly women: response to clinical trial information.J Clin Oncol 2006 Jul 20;24(21):3474-82.
    16849764
  • Punglia RS, Weeks JC, Neville BA, Earle CC.Effect of distance to radiation treatment facility on use of radiation therapy after mastectomy in elderly women.Int J Radiat Oncol Biol Phys 2006 Jun 29.
    16814955
  • Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.Cancer 2006 Jun 15;106(12):2576-82
    16703595
  • Christian CK, Niland J, Edge SB, Ottesen RA, Hughes ME, Theriault R, Wilson J, Hergrueter CA, Weeks JC.A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network.Ann Surg
    16432358
  • Buchholz TA, Theriault RL, Niland JC, Hughes ME, Ottesen R, Edge SB, Bookman MA, Weeks JC.The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers.J Clin Oncol 2006 Jan 20;24(3):361-9.
    16421417
  • Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G,.Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial.JAMA 2002 Jan 16;287(3):321-8.
    11790211
  • Burstein HJ, Gelber S, Guadagnoli E, Weeks JC.Use of alternative medicine by women with early-stage breast cancer.N Engl J Med 1999 Jun 3;340(22):1733-9.
    10352166
  • Weeks JC, Cook EF, O'Day SJ, Peterson LM, Wenger N, Reding D, Harrell FE, Kussin P, Dawson NV, Connors AF, Lynn J, Phillips RS.Relationship between cancer patients' predictions of prognosis and their treatment preferences.JAMA 1998 Jun 3;279(21):1709-14.
    9624023
  • Schrag D, Kuntz KM, Garber JE, Weeks JC.Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.N Engl J Med 1997 May 15;336(20):1465-71.
    9148160